Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses - PubMed (original) (raw)
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses
Guy M L Meno-Tetang et al. Drug Metab Dispos. 2006 Sep.
Abstract
FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis and prevention of solid organ transplant rejection. A physiologically based pharmacokinetic model was developed to predict the concentration of FTY720 in various organs of the body. Single oral and intravenous doses of FTY720 were administered to male Wistar rats, with blood and tissue sampling over 360 h analyzed by liquid chromatography/tandem mass spectrometry. A well stirred model (perfusion rate-limited) described FTY720 kinetics in heart, lungs, spleen, muscle, kidneys, bone, and liver, with a permeability rate-limited model being required for brain, thymus, and lymph nodes. Tissue-to-blood partition coefficients (RT) ranged from 4.69 (muscle) to 41.4 (lungs). In lymph nodes and spleen, major sites for FTY720-induced changes in sequestration of lymphocytes, RT values were 22.9 and 34.7, respectively. Permeability-surface area products for brain, thymus, and lymph nodes were 39.3, 122, and 176 ml/min. Intrinsic hepatic clearance was 23,145 l/h/kg for the free drug in blood (f(ub) 0.000333); systemic clearance was 0.748 l/h/kg and terminal half-life was 23.4 h. The fraction orally absorbed was 71%. The model characterized well FTY720 disposition for this extensive dosing and tissue collection study in the rat. On scaling the model to dogs and humans, good agreement was found between the actual and predicted blood concentration-time profiles. More importantly, brain concentrations in dogs were well predicted from those of the rat. In absolute terms, the predictions were slightly lower than observed values, just under a 1.5-fold deviation, but the model accurately predicted the terminal elimination of FTY720 from the brain.
Similar articles
- Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A. Foster CA, et al. J Pharmacol Exp Ther. 2007 Nov;323(2):469-75. doi: 10.1124/jpet.107.127183. Epub 2007 Aug 6. J Pharmacol Exp Ther. 2007. PMID: 17682127 - Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Kovarik JM, et al. J Clin Pharmacol. 2004 May;44(5):532-7. doi: 10.1177/0091270004264165. J Clin Pharmacol. 2004. PMID: 15102874 Clinical Trial. - FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH, Schmouder R. Skerjanec A, et al. J Clin Pharmacol. 2005 Nov;45(11):1268-78. doi: 10.1177/0091270005279799. J Clin Pharmacol. 2005. PMID: 16239360 Clinical Trial. - On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
Meno-Tetang GM, Lowe PJ. Meno-Tetang GM, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):182-92. doi: 10.1111/j.1742-7843.2005.pto960307.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733213 Review. - FTY720: early clinical experience.
Dragun D, Fritsche L, Boehler T, Peters H, Budde K, Neumayer HH. Dragun D, et al. Transplant Proc. 2004 Mar;36(2 Suppl):544S-548S. doi: 10.1016/j.transproceed.2003.12.048. Transplant Proc. 2004. PMID: 15041403 Review.
Cited by
- The emerging role of FTY720 as a sphingosine 1-phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms.
Naseh M, Vatanparast J, Rafati A, Bayat M, Haghani M. Naseh M, et al. Brain Behav. 2021 Jun;11(6):e02179. doi: 10.1002/brb3.2179. Epub 2021 May 10. Brain Behav. 2021. PMID: 33969931 Free PMC article. Review. - Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation.
Li Y, Zhang T, Li X, Zou P, Schwartz SJ, Sun D. Li Y, et al. Mol Nutr Food Res. 2013 Dec;57(12):2128-36. doi: 10.1002/mnfr.201300210. Epub 2013 Aug 9. Mol Nutr Food Res. 2013. PMID: 23929742 Free PMC article. - FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.
Vidal-Martinez G, Najera K, Miranda JD, Gil-Tommee C, Yang B, Vargas-Medrano J, Diaz-Pacheco V, Perez RG. Vidal-Martinez G, et al. Neuroscience. 2019 Jul 15;411:1-10. doi: 10.1016/j.neuroscience.2019.05.029. Epub 2019 May 23. Neuroscience. 2019. PMID: 31129200 Free PMC article. - Using an animal model to predict the effective human dose for oral multiple sclerosis drugs.
Liu W, Yu Z, Wang Z, Waubant EL, Zhai S, Benet LZ. Liu W, et al. Clin Transl Sci. 2023 Mar;16(3):467-477. doi: 10.1111/cts.13458. Epub 2022 Nov 23. Clin Transl Sci. 2023. PMID: 36419359 Free PMC article. - Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs.
Marsolais D, Yagi S, Kago T, Leaf N, Rosen H. Marsolais D, et al. Mol Pharmacol. 2011 Jan;79(1):61-8. doi: 10.1124/mol.110.066811. Epub 2010 Oct 8. Mol Pharmacol. 2011. PMID: 20935081 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources